As of 2025-06-03, the Intrinsic Value of Suven Life Sciences Ltd (SUVEN.NS) is (31.80) INR. This SUVEN.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 246.14 INR, the upside of Suven Life Sciences Ltd is -112.90%.
The range of the Intrinsic Value is (52.35) - (22.70) INR
Based on its market price of 246.14 INR and our intrinsic valuation, Suven Life Sciences Ltd (SUVEN.NS) is overvalued by 112.90%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (52.35) - (22.70) | (31.80) | -112.9% |
| DCF (Growth 10y) | (22.61) - (47.22) | (30.33) | -112.3% |
| DCF (EBITDA 5y) | (31.52) - (56.08) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (27.22) - (49.72) | (1,234.50) | -123450.0% |
| Fair Value | -32.87 - -32.87 | -32.87 | -113.35% |
| P/E | (214.42) - (201.93) | (198.35) | -180.6% |
| EV/EBITDA | (81.41) - (133.38) | (111.54) | -145.3% |
| EPV | (31.45) - (48.92) | (40.18) | -116.3% |
| DDM - Stable | (35.50) - (103.53) | (69.52) | -128.2% |
| DDM - Multi | (15.18) - (35.85) | (21.49) | -108.7% |
| Market Cap (mil) | 53,675.75 |
| Beta | 1.89 |
| Outstanding shares (mil) | 218.07 |
| Enterprise Value (mil) | 52,753.26 |
| Market risk premium | 8.31% |
| Cost of Equity | 13.34% |
| Cost of Debt | 8.51% |
| WACC | 13.34% |